Connecticut Medicaid and semaglutide
Wegovy for weight loss: no. Listed uses are preventing major heart events in patients with obesity and certain heart conditions, and MASH. Ozempic for weight loss: no. The department lists Ozempic for type 2 diabetes.; for type 2 diabetes Connecticut Medicaid must cover it. Read from Connecticut Department of Social Services documents Nov 6, 2026.
Wegovy · Connecticut Department of Social Services, presentation to the Medical Assistance Program Oversight Council
“For prevention of MACE (major adverse cardiac event) in patients with obesity and history of certain cardiovascular conditions”
read Nov 6, 2026
Ozempic · Connecticut Department of Social Services, presentation to the Medical Assistance Program Oversight Council
“For treatment of Type 2 diabetes (Ozempic, Trulicity, Victoza)”
read Nov 6, 2026
Ozempic · Connecticut Department of Social Services, hearing decision
“the medication approved for weight loss is limited to orlistat and phentermine.”
read Nov 6, 2026
In 2025 Connecticut Medicaid paid for 107,061 semaglutide prescriptions (Ozempic, Rybelsus, Wegovy), 61% of its GLP-1 prescriptions and 10th of the 50 states and DC. It reimbursed $120.5 million before rebates, $1,126 a prescription against $1,104 nationally.
| Brand | Prescriptions | Medicaid paid | Per Rx |
|---|---|---|---|
| Ozempic | 101,853 | $113.7 million | $1,116 |
| Rybelsus | 3,083 | $4.4 million | $1,426 |
| Wegovy | 2,125 | $2.5 million | $1,164 |
Semaglutide in the states around Connecticut
| State | Sell semaglutide, ship there | Cheapest | Medicaid Rx, 2025 | Medicaid, Wegovy for weight loss |
|---|---|---|---|---|
| Connecticut | 19 | $39/moWellmedr | 107,061 | Medicaid Wegovy: No |
| Massachusetts | 18 | $39/moWellmedr | 53,347 | Medicaid Wegovy: No |
| New York | 19 | $39/moWellmedr | 488,820 | Medicaid Wegovy: No |
| Rhode Island | 19 | $39/moWellmedr | 29,679 | Medicaid Wegovy: Not confirmed (KFF) |



